QIAGEN Expands QIAcuity Digital PCR Offering with Over 100 New Assays via the GeneGlobe Platform Page 1

QIAGEN Adds Over 100 New Validated QIAcuity Digital PCR Tests for Cancer Research, Inherited Genetic Disorders, Infectious Disease Surveillance and Other Applications // QIAcuity Digital PCR Enables Accurate and Sensitive Detection of Low-Abundance Pathogens, Copy Number Alterations, and Identification of Rare Mutations // Expanded Portfolio and Partnerships Support Increased Adoption of QIAcuity Across Multiple Application Areas

Venlo, Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a major milestone with the launch of 100 new assays for its QIAcuity digital PCR (dPCR) platform. These assays are used in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring.